Skip to main content
SpringerLink
Log in

Gastrointestinal Stromal Tumors

  • Chapter
  • First Online:
Book cover Gastrointestinal Oncology

  • 1676 Accesses

Abstract

Gastrointestinal stromal tumors (GISTs) though relatively rare are the most common mesenchymal tumors of the gastrointestinal tract. In the past treatment was mainly confined to surgical resection. These tumors are relatively resistant to chemotherapy and radiotherapy. Recent understanding of pathogenesis especially the role of gain of function KIT gene mutations has enabled the rationale development of effective targeted therapies such imatinib mesylate in a relatively short period of time for both the advanced and adjuvant settings. Sunitinib, a multikinase inhibitor, has also been proven as second line therapy and other biological agents such as nilotinib and sorafenib are in clinical testing. Mutational analysis of GIST contributes predictive and prognostic information helping to guide biological therapies. The multidisciplinary management of GIST has also challenged some traditional oncological paradigms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adenis A et al (2008) Does interruption of imatinib (IM) in responding patients after three years of treatment influence outcome of patients with advanced GIST included in the BFR14 trial? J Clin Oncol 26:10522 (Meeting Abstracts)

    Google Scholar 

  • Agaimy A et al (2006) Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol 23:120–129

    Article  PubMed  Google Scholar 

  • Agaram NP et al (2008a) Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 14:3204–3215

    Article  CAS  PubMed  Google Scholar 

  • Agaram NP et al (2008b) Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 47:853–859

    Article  CAS  PubMed  Google Scholar 

  • American Gastroenterological Association Institute (2006) American Gastroenterological Association Institute medical position statement on the management of gastric subepithelial masses. Gastroenterology 130:2215–2216

    Article  Google Scholar 

  • Antonescu CR et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11:4182–4190

    Article  CAS  PubMed  Google Scholar 

  • Bauer S et al (2006) Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66:9153–9161

    Article  CAS  PubMed  Google Scholar 

  • Benjamin R et al (2006) Initial results of a multicenter single-arm phase 2 study of AMG706, an oral multikinase inhibitor, for the treatment of advanced imatinib-resistant gastrointestinal stromal tumors (GIST). In: 12th annual meeting of the connective tissue oncology society, Venice, Italy

    Google Scholar 

  • Benjamin RS et al (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760–1764

    Article  PubMed  Google Scholar 

  • Blackstein ME et al (2006) Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol 20:157–163

    PubMed  Google Scholar 

  • Blanke CD et al (2008a) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625

    Article  CAS  PubMed  Google Scholar 

  • Blanke CD et al (2008b) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626–632

    Article  CAS  PubMed  Google Scholar 

  • Blay JY et al (2005) Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol 16:566–578

    Article  PubMed  Google Scholar 

  • Blay JY et al (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25:1107–1113

    Article  CAS  PubMed  Google Scholar 

  • Blay JY et al (2008) A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): study update. J Clin Oncol 26:10553 (Meeting Abstracts)

    Google Scholar 

  • Bonvalot S et al (2006) Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 13:1596–1603

    Article  CAS  PubMed  Google Scholar 

  • Braconi C et al (2008) Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 19:1293–1298

    Article  CAS  PubMed  Google Scholar 

  • Cameron S et al (2009) Analysis of a case with disappearance of the primary gastrointestinal stromal tumor and progressive liver metastases under long-term treatment with tyrosine kinase inhibitors. Med Oncol 27(2):213–218

    Article  PubMed  Google Scholar 

  • Carney JA (1999) Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 74:543–552

    Article  CAS  PubMed  Google Scholar 

  • Carney JA, Stratakis CA (2002) Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet 108:132–139

    Article  PubMed  Google Scholar 

  • Casali P et al (2005) Imatinib mesylate in advanced gastrointestinal stromal tumors (GIST): survival analysis of the intergroup EORTC/ISG/AGITG randomized trial in 946 patients. Eur J Cancer Suppl 3:201

    Google Scholar 

  • Casali PG et al (2008) Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(suppl 2):ii35–ii38

    Google Scholar 

  • Choi H et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759

    Article  PubMed  Google Scholar 

  • Corless CL et al (2002) KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160:1567–1572

    CAS  PubMed  Google Scholar 

  • Croom KF, Perry CM (2003) Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 63:513–522, discussion 523–514

    Article  CAS  PubMed  Google Scholar 

  • Crosby JA et al (2001) Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 8:50–59

    Article  CAS  PubMed  Google Scholar 

  • Debiec-Rychter M et al (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093–1103

    Article  CAS  PubMed  Google Scholar 

  • DeMatteo RP et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58

    Article  CAS  PubMed  Google Scholar 

  • DeMatteo R et al (2007a) Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. Proc Am Soc Clin Oncol (Abstr 10079)

    Google Scholar 

  • DeMatteo RP et al (2007b) Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245:347–352

    Article  PubMed  Google Scholar 

  • DeMatteo R et al (2008) Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000. In: ASCO Gastrointestinal Cancers Symposium (Abstr 8)

    Google Scholar 

  • Demetri GD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480

    Article  CAS  PubMed  Google Scholar 

  • Demetri GD et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338

    Article  CAS  PubMed  Google Scholar 

  • Demetri GD et al (2007) NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5(Suppl 2):S1–S29, quiz S30

    PubMed  Google Scholar 

  • Demetri G et al. (2008) Correlation of imatinib plasma levels with clinical benefit in patients (Pts) with unresectable/metastatic gastrointestinal stromal tumors (GIST). In: ASCO Gastrointestinal Cancers Symposium

    Google Scholar 

  • Desai J et al (2006) Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660–664

    PubMed  Google Scholar 

  • Doric M et al (2007) Testicular metastasis of gastrointestinal stromal tumor of the jejunum. Bosn J Basic Med Sci 7:176–179

    PubMed  Google Scholar 

  • Duffaud F et al (2009) Time to secondary resistance (TSR) after interruption of imatinib: updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival. J Clin Oncol 27:10508 (Meeting Abstracts)

    Google Scholar 

  • Dumez H et al (2008) A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST). J Clin Oncol 26:10519 (Meeting Abstracts)

    Google Scholar 

  • Eisenberg BL (2006) Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials. Clin Colorectal Cancer 6(Suppl 1):S24–S29

    Article  CAS  PubMed  Google Scholar 

  • Eisenberg BL, Judson I (2004) Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 11:465–475

    Article  PubMed  Google Scholar 

  • Eisenberg BL et al (2009) Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 99:42–47

    Article  CAS  PubMed  Google Scholar 

  • Espinosa I et al (2008) A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 32:210–218

    Article  PubMed  Google Scholar 

  • Everett M, Gutman H (2008) Surgical management of gastrointestinal stromal tumors: analysis of outcome with respect to surgical margins and technique. J Surg Oncol 98:588–593

    Article  PubMed  Google Scholar 

  • Fiore M et al (2009) Preoperative imatinib for unresectable or locally advanced primary gastrointestinal stomal tumors (GIST). Eur J Canc Surg xx:1–7

    Google Scholar 

  • Fletcher CD et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459–465

    Article  PubMed  Google Scholar 

  • Fletcher J et al (2003) Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST) (abstract). Proc Am Soc Clin Oncol 22:815

    Google Scholar 

  • Gelderblom H et al (2009) Sorafenib fourth-line treatment in imatinib, sunitinib, and nilotinib resistant metastatic GIST: a retrospective analysis. ASCO Gastrointestinal Cancers Symposium (Abstr 51)

    Google Scholar 

  • George S et al (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45(11):1959–1968

    Article  CAS  PubMed  Google Scholar 

  • Godwin A et al (2008) Insulin-like growth factor 1 receptor (IGF-1R): a potential therapeutic target for gastrointestinal stromal tumors (GIST). J Clin Oncol 26:10507 (Meeting Abstracts)

    Google Scholar 

  • Goettsch WG et al (2005) Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 41:2868–2872

    Article  PubMed  Google Scholar 

  • Goh BK et al (2008) Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria. Ann Surg Oncol 15:2153–2163

    Article  PubMed  Google Scholar 

  • Gold JS, Dematteo RP (2006) Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 244:176–184

    Article  PubMed  Google Scholar 

  • Guo T et al (2007) Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 13:4874–4881

    Article  CAS  PubMed  Google Scholar 

  • Gurney H et al (2007) Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 82:33–40

    Article  CAS  PubMed  Google Scholar 

  • Harrison ML, Goldstein D (2006) Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach. Intern Med J 36:367–377

    Article  CAS  PubMed  Google Scholar 

  • Heinrich MC et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26:5352–5359

    Article  CAS  PubMed  Google Scholar 

  • Hirota S et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580

    Article  CAS  PubMed  Google Scholar 

  • Hughes B et al (2004) Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report. BMC Cancer 4:74

    Article  PubMed  Google Scholar 

  • Hwang JH et al (2006) American Gastroenterological Association Institute technical review on the management of gastric subepithelial masses. Gastroenterology 130:2217–2228

    Article  PubMed  Google Scholar 

  • Janeway KA et al (2007) Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 67:9084–9088

    Article  CAS  PubMed  Google Scholar 

  • Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39:1411–1419

    Article  PubMed  Google Scholar 

  • Joensuu H et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056

    Article  CAS  PubMed  Google Scholar 

  • Judson I et al (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 55:379–386

    Article  CAS  PubMed  Google Scholar 

  • Kawanowa K et al (2006) High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 37:1527–1535

    Article  PubMed  Google Scholar 

  • Lamuraglia M et al (2006) Dynamic contrast-enhanced Doppler ultrasound (DCE-US) is a useful radiological assessment to early predict the outcome of patients with gastrointestinal stromal tumors (GIST) treated with imatinib (IM). J Clin Oncol 24:9539 (Meeting Abstracts)

    Google Scholar 

  • Lee HE et al (2008) Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining. J Clin Pathol 61:722–729

    Article  CAS  PubMed  Google Scholar 

  • Liegl B et al (2009) Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am J Surg Pathol 33:218–226

    Article  PubMed  Google Scholar 

  • Mazzarolo S, Brady P (2007) Small bowel capsule endoscopy: a systematic review. South Med J 100:274–280

    PubMed  Google Scholar 

  • Mendoza-Marin M et al (2002) Malignant stromal tumor of the gallbladder with interstitial cells of Cajal phenotype. Arch Pathol Lab Med 126:481–483

    PubMed  Google Scholar 

  • Miettenen M et al (2002) Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 38:S39–S51

    Article  Google Scholar 

  • Miettinen M, Lasota J (2006a) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23:70–83

    Article  PubMed  Google Scholar 

  • Miettinen M, Lasota J (2006b) Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130:1466–1478

    CAS  PubMed  Google Scholar 

  • Miettinen M et al (2005a) Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 29:1373–1381

    Article  PubMed  Google Scholar 

  • Miettinen M et al (2005b) Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 29:1373–1381

    Article  PubMed  Google Scholar 

  • Miettinen M et al (2005c) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29:52–68

    Article  PubMed  Google Scholar 

  • Miettinen M et al (2006) Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 30:90–96

    Article  PubMed  Google Scholar 

  • Miettinen M et al (2008) A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia. Cancer 112:645–649

    Article  PubMed  Google Scholar 

  • Mussi C et al (2008a) Gastrointestinal stromal tumor of the rectum and rectovaginal space: a retrospective review. J Clin Oncol 26:10560 (Meeting Abstracts)

    Google Scholar 

  • Mussi C et al (2008b) Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res 14:4550–4555

    Article  CAS  PubMed  Google Scholar 

  • Negri T et al (2009) Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). J Pathol 217:103–112

    Article  CAS  PubMed  Google Scholar 

  • Nilsson B et al (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western Sweden. Cancer 103:821–829

    Article  PubMed  Google Scholar 

  • Nilsson B et al (2007) Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 96:1656–1658

    Article  CAS  PubMed  Google Scholar 

  • Park JK et al (2004) Malignant gastrointestinal stromal tumor of the gallbladder. J Korean Med Sci 19:763–767

    Article  PubMed  Google Scholar 

  • Pasku D et al (2008) Bilateral gluteal metastases from a misdiagnosed intrapelvic gastrointestinal stromal tumor. World J Surg Oncol 6:139

    Article  PubMed  Google Scholar 

  • Patel S et al (1991) Evaluation of ifosfamide in metastastic leiomyosarcoma of gastrointestinal origin. Proc Am Soc Clin Oncol 10:352

    Google Scholar 

  • Pidhorecky I et al (2000) Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 7:705–712

    Article  CAS  PubMed  Google Scholar 

  • Plager C et al (1991) Adriamycin based chemotherapy for leiomyosarcoma of the stomach and small bowel. Proc Am Soc Clin Oncol 10:352

    Google Scholar 

  • Pollock J et al (2001) Adjuvant radiotherapy for gastrointestinal stromal tumor of the rectum. Dig Dis Sci 46:268–272

    Article  CAS  PubMed  Google Scholar 

  • Raut CP et al (2006) Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24:2325–2331

    Article  CAS  PubMed  Google Scholar 

  • Rossi G et al (2005) PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract. Histopathology 46:522–531

    Article  CAS  PubMed  Google Scholar 

  • Rutkowski P et al (2006) Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 93:304–311

    Article  PubMed  Google Scholar 

  • Schneider-Stock R et al (2005) Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 11:638–645

    CAS  PubMed  Google Scholar 

  • Shankar S et al (2005) Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 235:892–898

    Article  PubMed  Google Scholar 

  • Stroobants S et al (2003) 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012–2020

    Article  CAS  PubMed  Google Scholar 

  • Takahashi T et al (2007) An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol 12:369–374

    Article  CAS  PubMed  Google Scholar 

  • Tarn C et al (2008) Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A 105:8387–8392

    Article  CAS  PubMed  Google Scholar 

  • The NCCN Clinical Practice Guidelines in Oncology (2008) Soft tissue sarcoma (V.2.2009). National Comprehensive Cancer Network, Fort Washington

    Google Scholar 

  • Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  CAS  PubMed  Google Scholar 

  • Torihashi S et al (1999) Blockade of kit signaling induces transdifferentiation of interstitial cells of cajal to a smooth muscle phenotype. Gastroenterology 117:140–148

    Article  CAS  PubMed  Google Scholar 

  • Trent J et al (2003) A two arm phase 2 study of temozolomide (T) in gastrointestinal stromal tumors (GISTs) and other soft-tissue sarcomas (STS). Proc Am Soc Clin Oncol 22:3298

    Google Scholar 

  • Tuveson DA et al (2001) STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20:5054–5058

    Article  CAS  PubMed  Google Scholar 

  • Van Glabbeke M et al (2006) Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 42:2277–2285

    Article  PubMed  Google Scholar 

  • Van Glabbeke MM et al (2007) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analyis based on 1,640 patients (pts). J Clin Oncol 25:10004 (Meeting Abstracts)

    Google Scholar 

  • van Oosterom AT et al (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421–1423

    Article  PubMed  Google Scholar 

  • van Oosterom A et al (2005) A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: study update. J Clin Oncol 23:9033 (Meeting Abstracts)

    Google Scholar 

  • Verweij J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134

    Article  CAS  PubMed  Google Scholar 

  • Von Mehren M et al (2007) A phase I study of nilotinib alone and in combination with imatinib (IM) in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) – study update. J Clin Oncol 25:10023 (Meeting Abstracts)

    Google Scholar 

  • von Mehren M et al (2008) Imatinib pharmacokinetics (PK) and its correlation with clinical response in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol 26:4523 (Meeting Abstracts)

    Google Scholar 

  • Wagner AJ et al (2008) Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from phase I trial. J Clin Oncol 26:10503 (Meeting Abstracts)

    Google Scholar 

  • Wardelmann E et al (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12:1743–1749

    Article  CAS  PubMed  Google Scholar 

  • West RB et al (2004) The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 165:107–113

    CAS  PubMed  Google Scholar 

  • White DL et al (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108:697–704

    Article  CAS  PubMed  Google Scholar 

  • Widmer N et al (2006) Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 62:97–112

    Article  CAS  PubMed  Google Scholar 

  • Wiebe L et al (2008) Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol 26:10502 (Meeting Abstracts)

    Google Scholar 

  • Yamada Y et al (2008) Phase II study of motesanib diphosphate (AMG 706) in Japanese patients (pts) with advanced gastrointestinal stromal tumors (GISTs) who developed progressive disease or relapsed while on imatinib mesylate. Gastrointestinal Cancers Symposium (Abstr 107)

    Google Scholar 

  • Yantiss RK et al (2002) Gastrointestinal stromal tumors: an ultrastructural study. Int J Surg Pathol 10:101–113

    Article  PubMed  Google Scholar 

  • Zalcberg JR et al (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41:1751–1757

    Article  CAS  PubMed  Google Scholar 

  • Zhan WH; China Gastrointestinal Cooperative Group (2007) Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST. J Clin Oncol 25:10045 (Meeting Abstracts)

    Google Scholar 

Download references

Acknowledgments

The authors would acknowledge the assistance of Mark Koina of the Electron Microscopy Unit at ACT Pathology, The Canberra Hospital in supplying the electron microscopy image and Rod Hicks from the Centre for Molecular Imaging, Peter MacCallum Cancer Centre for providing the PET/CT images.

Author information

Authors and Affiliations

  1. Division of cancer medicine, Peter MacCallum Cancer Centre and Dept of medicine, University of Melbourne, Melbourne, VIC, Australia

    John R. Zalcberg

  2. Medical Oncology Unit, The Canberra Hospital, ANU Medical School, Australian National University, Canberra, ACT, Australia

    Desmond Yip

  3. ACT Pathology, The Canberra Hospital, ANU Medical School, Australian National University, Canberra, ACT, Australia

    Christine Hemmings

  4. Peter MacCallum Cancer Center, Melbourne, VIC, Australia

    Bruce Mann

  5. Division of Medical Oncology, UBC, Vancouver, BC, Canada

    Charles D. Blanke

Authors
  1. John R. Zalcberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Desmond Yip
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christine Hemmings
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bruce Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Charles D. Blanke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John R. Zalcberg .

Editor information

Editors and Affiliations

  1. Div. Medical Oncology, University of British Columbia, West 10th Avenue 600, Vancouver, V5Z 4E6, British Columbia, Canada

    Charles D. Blanke

  2. FB 19 Zentrum der Radiologie, Klinik f. Strahlentherapie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, Frankfurt, 60590, Germany

    Claus Rödel

  3. Evanston Northwestern Healthcare, Northwestern University, Ridge Ave. 2650, Evanston, 60201, Illinois, USA

    Mark S. Talamonti

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Zalcberg, J.R., Yip, D., Hemmings, C., Mann, B., Blanke, C.D. (2011). Gastrointestinal Stromal Tumors. In: Blanke, C., Rödel, C., Talamonti, M. (eds) Gastrointestinal Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13306-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-13306-0_6

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-13305-3

  • Online ISBN: 978-3-642-13306-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation